Abstract:Abstract Unrelated donor allogeneic hematopoietic stem cell transplantation (URD-HSCT) can potentially cure a variety of hematological malignancies. Until now, there were 140 cases of URD-HSCT in our bone marrow transplantation center, and we would retrospectively analyze the results of 128 patients received URD-HSCT between Nov. 1998 and May. 2006. The median age of all patients was 28 years (range 8–52 years), 27 patients with ALL in CR1, 28 patients with AML (26 in CR1 and 2 in CR2), 64 patients with CML (59 in CP, 1 in AP and 4 in BP), 8 patients with MDS, and 1 patient with MM. 113 patients were received Bu/Cy2 regimen as conditioning with busulfan 16mg/kg plus cyclophosphamide 120mg/kg, while other 5 patients with CML were received reduced intensity conditioning (RIC) regimen consisted of fludarabine (30mg/m2/d), busulfan (3.2mg/kg/d, i.v.) and ATG (5mg/kg/d). Graft with a median number of total nucleated cells was 3.45×108/kg (range 1.72–10.50×108/kg), including CD34+ cells 4.77×106/kg (range 0.72–9.92×106/kg) and CFU-GM 2.73×105/kg (range 1.46–7.91×105/kg). 110 patients were given MMF (0.5g/d), combined with CsA (3mg/kg/d) and short course MTX (10mg/m2/d) to prevent aGVHD. 18 patients received additional anti-CD25 monoclonal antibody 50mg/d on day 0, +4. Lipo protaglandin E1 was given to prevent SOS and CMV-PP65 antigen was monitored after the transplantation and ganciclovir was used to prevent CMV infection. Hemopoietic recovery was observed in 123 evaluable patients, and the median time to achieve ANC>0.5×109/L was 17 days (range 12–31 days), platelets >20×109/L was 24 days (range 8–140 days). aGVHD developed in 69 (56.10%) patients; aGVHD of grade I-II were observed in 53 (43.09%) patients and the severe aGVHD of grade III-IV were observed in 16 (13.01%) patients. cGVHD developed in 53 (46.49%) patients with 46 (40.35%) limited and 7 (6.14%) extensive. In group (n=110) which received MMF combined with CsA and MTX as aGVHD prophylaxis, aGVHD were observed in 60 (54.55%) patients with grade I-II 42.73% and grade III-IV 11.82%. While in group (n=18) which received additional anti-CD25 monoclonal antibody, aGVHD were observed in 7 (46.7%) patients with grade I-II 6 (33.3%) and grade III-IV 3 (16.67%). There was no significant difference between two regimen of aGVHD prophylaxis. Early TRM of all patients was 10.94% at 100 days after transplant. After a median follow-up of 13.2 months (range 1.3–92 months), clinical relapse were detected in 8 patients. By Kaplan-Meier method, the accumulative probability of 5-year overall survival of all patients was 60.98±4.52%, and which of ALL, AML, CML, MDS were 68.65±9.21%, 61.61±9.74%, 56.95±6.50% and 75.00±15.31%, respectively. 4 of 5 patients received reduced intensity URD-HSCT with follow-up of 7.3 months (range 3.0–10.3 months) experienced successful engraftment, and no aGVHD developed while cGVHD occurred in 2 cases, all patients achieved disease free survival. To further examined the impact of HLA matching on GVHD and survival, we compared the outcomes of the HLA-matched group (n=82) and HLA 1–2 alleles disparity mismatched group (n=46). aGVHD were observed in 38 (46.34%) patients in HLA-matched group and 31 (67.39%) patients in HLA-mismatched group (P<0.05), respectively. The survival of HLA-matched and HLA-mismatched group were 69.14% and 52.17% (P<0.05) respectively. URD-HSCT could be one of choice in patients with ALL, AML, CML, MDS, and HLA class I and class II matching would be associated with the outcomes of URD-HSCT.

Outcomes Of Unrelated Donor Hematopoietic Stem Cell Transplantation For Hematological Malignancy: A Single Center'S Experience.

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

The role of donor type and pre‐transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia

Upfront alternate donor HSCT for children with severe aplastic anemia: a single center prospective clinical trail outcome

Comparison of upfront haploidentical hematopoietic stem cell transplantation and salvage haploidentical hematopoietic stem cell transplantation after immunosuppressive therapy in children with acquired severe aplastic anemia - a multicenter study

Outcome of 64 Aplastic Anemia Children with Allogenic Hematopoietic Stem Cell Transplant in China: A Report from Chinese Pediatric Group of HSCT

HLA‐haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties

Upfront Umbilical Cord Blood Transplantation Versus Immunosuppressive Therapy for Pediatric Patients with Idiopathic Severe Aplastic Anemia

Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acquired Severe Aplastic Anemia: Collaborative Study of Three Eastern Asian Countries

First‐line Choice for Severe Aplastic Anemia in Children: Transplantation from a Haploidentical Donor Vs Immunosuppressive Therapy

First-Line Choice For Severe Aplastic Anemia In Children: Transplantation From A Haplo-Identical Donor Versus Immunosuppressive Therapy

Unmanipulated haploidentical haematopoietic stem cell transplantation for children with severe aplastic anaemia

Outpatient ATG-free hematopoietic transplantation for aplastic anemia in limited-resource environments offers excellent results: Data from a single LATAM center

Allogeneic Hematopoietic Stem Cell Transplant Offer Good Outcomes in Pediatric Aplastic Anemia: Experience From Developing World

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT

Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia

Allogeneic Stem Cell Transplantation for Children with Acquired Severe Aplastic Anaemia: a Retrospective Study by the Viva‐Asia Blood and Marrow Transplantation Group

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia

CD34+ Stem Cell Selection and CD3+ T Cell Add-Back from Matched Unrelated Adult Donors in Children with Primary Immunodeficiencies and Hematological Diseases

S239: COMPARABLE LONG-TERM OUTCOMES BETWEEN UPFRONT HAPLOIDENTICAL AND IDENTICAL SIBLING DONOR HSCT IN APLASTIC ANEMIA: A NATIONAL REGISTRY-BASED STUDY